Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment.
Antineoplastic Agents
/ chemistry
Apoptosis
/ drug effects
Autophagy
/ drug effects
Biological Products
/ chemistry
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cisplatin
/ pharmacology
Drug Resistance, Neoplasm
Drug Synergism
Drug Therapy, Combination
Humans
Prodigiosin
/ chemistry
Urinary Bladder Neoplasms
/ drug therapy
apoptosis
autophagy
chemoresistance
cisplatin
prodigiosin
urothelial carcinoma
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
27 Feb 2021
27 Feb 2021
Historique:
received:
22
12
2020
revised:
12
02
2021
accepted:
22
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
21
4
2021
Statut:
epublish
Résumé
Cisplatin-based treatment is the standard of care therapy for urothelial carcinomas. However, complex cisplatin resistance mechanisms limit the success of this approach. Both apoptosis and autophagy have been shown to contribute to this resistance. Prodigiosin, a secondary metabolite from various bacteria, exerts different biological activities including the modulation of these two cellular stress response pathways. We analyzed the effect of prodigiosin on protein levels of different autophagy- and apoptosis-related proteins in cisplatin-sensitive and -resistant urothelial carcinoma cells (UCCs). Furthermore, we investigated the effect on cell viability of prodigiosin alone or in combination with cisplatin. We made use of four different pairs of cisplatin-sensitive and -resistant UCCs. We found that prodigiosin blocked autophagy in UCCs and re-sensitized cisplatin-resistant cells to apoptotic cell death. Furthermore, we found that prodigiosin is a potent anticancer agent with nanomolar IC
Identifiants
pubmed: 33673611
pii: molecules26051294
doi: 10.3390/molecules26051294
pmc: PMC7957586
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Biological Products
0
Prodigiosin
OL369FU7CJ
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : STO 864/5-1
Organisme : Deutsche Forschungsgemeinschaft
ID : STO 864/6-1
Organisme : Deutsche Forschungsgemeinschaft
ID : GK 2158
Organisme : Bundesministerium für Bildung und Forschung
ID : 031B0918A - project 'AutoBiotech'
Références
J Clin Med. 2018 Oct 21;7(10):
pubmed: 30347872
Apoptosis. 2018 Jun;23(5-6):314-328
pubmed: 29721785
Cancer Manag Res. 2019 Apr 12;11:2987-2995
pubmed: 31114346
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:375-398
pubmed: 28061686
Front Microbiol. 2015 Sep 15;6:972
pubmed: 26441905
Pharmacol Res. 2014 Apr;82:1-8
pubmed: 24657238
Mol Cancer. 2020 Jan 22;19(1):12
pubmed: 31969156
Lung Cancer. 2014 Sep;85(3):420-8
pubmed: 24997137
Pharmacol Rev. 2012 Jul;64(3):706-21
pubmed: 22659329
J Appl Microbiol. 2018 Oct;125(4):1017-1029
pubmed: 29896797
ACS Synth Biol. 2017 Sep 15;6(9):1757-1765
pubmed: 28505410
Biochim Biophys Acta. 2012 Jan;1824(1):68-88
pubmed: 22024571
Prog Nucleic Acid Res Mol Biol. 2001;67:93-130
pubmed: 11525387
Int J Mol Sci. 2018 Nov 04;19(11):
pubmed: 30400387
Transl Androl Urol. 2019 Feb;8(1):5-11
pubmed: 30976562
Drug Resist Updat. 2015 May;20:1-11
pubmed: 26003720
Toxicol In Vitro. 2019 Oct;60:107-115
pubmed: 31077745
Front Oncol. 2018 Dec 05;8:573
pubmed: 30568916
PLoS One. 2016 Sep 09;11(9):e0162412
pubmed: 27612193
Medicine (Baltimore). 2018 Nov;97(46):e12912
pubmed: 30431566
Curr Med Chem. 2010;17(21):2222-31
pubmed: 20459382
J Mol Biol. 2020 Apr 3;432(8):2462-2482
pubmed: 31682838
Front Microbiol. 2019 Jul 24;10:1715
pubmed: 31396200
J Urol. 2014 Jun;191(6):1889-98
pubmed: 24440234
J Mol Graph Model. 2020 Jul;98:107614
pubmed: 32289740
J Cell Sci. 2004 Oct 1;117(Pt 21):5155-64
pubmed: 15456852
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
pubmed: 11259830
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13150-13155
pubmed: 27799526
Cell Mol Life Sci. 2015 Dec;72(24):4721-57
pubmed: 26390974
Int J Mol Sci. 2018 Feb 16;19(2):
pubmed: 29462944
Biochem Biophys Res Commun. 2020 Dec 10;533(3):474-480
pubmed: 32977950
Expert Rev Anticancer Ther. 2012 Feb;12(2):271-81
pubmed: 22316374
Sci Rep. 2019 Oct 9;9(1):14476
pubmed: 31597922
Nature. 1967 Mar 4;213(5079):903-4
pubmed: 6030049
Leuk Lymphoma. 2015;56(12):3336-42
pubmed: 25971907
Future Microbiol. 2007 Dec;2(6):605-18
pubmed: 18041902
Hum Exp Toxicol. 2017 Apr;36(4):402-411
pubmed: 27334973
Cancer Sci. 2017 Jul;108(7):1405-1413
pubmed: 28498503
Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9
pubmed: 20709666
Chem Rev. 2016 Jul 27;116(14):7818-53
pubmed: 27314508
Urol Oncol. 2018 Apr;36(4):160.e1-160.e13
pubmed: 29276062
Br J Cancer. 2003 Apr 22;88(8):1327-34
pubmed: 12698203
Front Pharmacol. 2017 Apr 20;8:158
pubmed: 28473769
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Int J Mol Sci. 2019 Aug 24;20(17):
pubmed: 31450627
Cancer Lett. 2020 Jul 1;481:15-23
pubmed: 32184145
Cancer Treat Rev. 2019 Jun;76:10-21
pubmed: 31030123
Autophagy. 2010 Nov;6(8):1042-56
pubmed: 21121091
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
Invest New Drugs. 2021 Apr;39(2):538-563
pubmed: 33159673
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033
World J Urol. 2020 Aug;38(8):1895-1904
pubmed: 31676912
Cancer Lett. 2014 Dec 1;355(1):34-45
pubmed: 25236911
Oncol Rep. 2019 Jun;41(6):3377-3385
pubmed: 30942457